BACKGROUND: Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas. AIMS: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs. METHODS: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing. RESULTS: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas. CONCLUSION: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.
BACKGROUND:Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas. AIMS: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs. METHODS: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing. RESULTS:BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas. CONCLUSION: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.
Authors: Alexis Gorden; Iman Osman; Weiming Gai; Dan He; Weiqing Huang; Anne Davidson; Alan N Houghton; Klaus Busam; David Polsky Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701
Authors: Janet L Maldonado; Jane Fridlyand; Hetal Patel; Ajay N Jain; Klaus Busam; Toshiro Kageshita; Tomomichi Ono; Donna G Albertson; Dan Pinkel; Boris C Bastian Journal: J Natl Cancer Inst Date: 2003-12-17 Impact factor: 13.506
Authors: Jianli Dong; Robert G Phelps; Rui Qiao; Shen Yao; Outhiriaradjou Benard; Zeev Ronai; Stuart A Aaronson Journal: Cancer Res Date: 2003-07-15 Impact factor: 12.701
Authors: Julia Reifenberger; Christiane B Knobbe; Astrid A Sterzinger; Britta Blaschke; Klaus W Schulte; Thomas Ruzicka; Guido Reifenberger Journal: Int J Cancer Date: 2004-04-10 Impact factor: 7.396
Authors: Amir S Yazdi; Gabriele Palmedo; Michael J Flaig; Ursula Puchta; Andrea Reckwerth; Arno Rütten; Thomas Mentzel; Heino Hügel; Markus Hantschke; Monika-Hildegard Schmid-Wendtner; Heinz Kutzner; Christian A Sander Journal: J Invest Dermatol Date: 2003-11 Impact factor: 8.551
Authors: Frank Cruz; Brian P Rubin; David Wilson; Ajia Town; Arin Schroeder; Andrea Haley; Troy Bainbridge; Michael C Heinrich; Christopher L Corless Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Piotr Waloszczyk; Marek Masiuk; Jaroslaw Wejman; Justyna Szumilo; Markku Miettinen Journal: Mod Pathol Date: 2019-02-13 Impact factor: 7.842
Authors: Lisa A Kottschade; Travis E Grotz; Roxana S Dronca; Diva R Salomao; Jose S Pulido; Nabil Wasif; James W Jakub; Sanjay P Bagaria; Riten Kumar; Judith S Kaur; Shane Y Morita; Steven L Moran; Jesse T Nguyen; Emily C Nguyen; Jennifer L Hand; Lori A Erickson; Jerry D Brewer; Christian L Baum; Robert C Miller; David L Swanson; Val Lowe; Svetomir N Markovic Journal: Am J Clin Oncol Date: 2014-12 Impact factor: 2.339
Authors: Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn Journal: Virchows Arch Date: 2012-12-08 Impact factor: 4.064
Authors: Michael R Lang; Larissa B Patterson; Tiffany N Gordon; Stephen L Johnson; David M Parichy Journal: PLoS Genet Date: 2009-11-26 Impact factor: 5.917